Emily Bowman1, Nicholas T Funderburg2. 1. School of Health and Rehabilitation Sciences, Division of Medical Laboratory Science, Ohio State University College of Medicine, 453 W. 10th Ave. 535A Atwell Hall, Columbus, OH, 43210, USA. 2. School of Health and Rehabilitation Sciences, Division of Medical Laboratory Science, Ohio State University College of Medicine, 453 W. 10th Ave. 535A Atwell Hall, Columbus, OH, 43210, USA. Nicholas.Funderburg@osumc.edu.
Abstract
PURPOSE OF REVIEW: Human immunodeficiency virus (HIV) infection and its treatment with antiretroviral therapy (ART) are associated with lipid abnormalities that may enhance cardiovascular disease risk (CVD). RECENT FINDINGS: Chronic inflammation persists in HIV+ individuals, and complex relationships exist among lipids and inflammation, as immune activation may be both a cause and a consequence of lipid abnormalities in HIV infection. Advances in mass spectrometry-based techniques now allow for detailed measurements of individual lipid species; improved lipid measurement might better evaluate CVD risk compared with the prognostic value of traditional assessments. Lipidomic analyses have begun to characterize dynamic changes in lipid composition during HIV infection and following treatment with ART, and further investigation may identify novel lipid biomarkers predictive of adverse outcomes. Developing strategies to improve management of comorbidities in the HIV+ population is important, and statin therapy and lifestyle modifications, including diet and exercise, may help to improve lipid levels and mitigate CVD risk.
PURPOSE OF REVIEW: Human immunodeficiency virus (HIV) infection and its treatment with antiretroviral therapy (ART) are associated with lipid abnormalities that may enhance cardiovascular disease risk (CVD). RECENT FINDINGS:Chronic inflammationpersists in HIV+ individuals, and complex relationships exist among lipids and inflammation, as immune activation may be both a cause and a consequence of lipid abnormalities in HIV infection. Advances in mass spectrometry-based techniques now allow for detailed measurements of individual lipid species; improved lipid measurement might better evaluate CVD risk compared with the prognostic value of traditional assessments. Lipidomic analyses have begun to characterize dynamic changes in lipid composition during HIV infection and following treatment with ART, and further investigation may identify novel lipid biomarkers predictive of adverse outcomes. Developing strategies to improve management of comorbidities in the HIV+ population is important, and statin therapy and lifestyle modifications, including diet and exercise, may help to improve lipid levels and mitigate CVD risk.
Authors: Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek Journal: Nat Med Date: 2006-11-19 Impact factor: 53.440
Authors: Anoop S V Shah; Dominik Stelzle; Kuan Ken Lee; Eduard J Beck; Shirjel Alam; Sarah Clifford; Chris T Longenecker; Fiona Strachan; Shashwatee Bagchi; William Whiteley; Sanjay Rajagopalan; Shyamasundaran Kottilil; Harish Nair; David E Newby; David A McAllister; Nicholas L Mills Journal: Circulation Date: 2018-09-11 Impact factor: 29.690
Authors: Zahedi Mujawar; Honor Rose; Matthew P Morrow; Tatiana Pushkarsky; Larisa Dubrovsky; Nigora Mukhamedova; Ying Fu; Anthony Dart; Jan M Orenstein; Yuri V Bobryshev; Michael Bukrinsky; Dmitri Sviridov Journal: PLoS Biol Date: 2006-10 Impact factor: 8.029
Authors: Manjusha M Kulkarni; Annette N Ratcliff; Menakshi Bhat; Yazan Alwarawrah; Philip Hughes; Jesus Arcos; David Loiselle; Jordi B Torrelles; Nicholas T Funderburg; Timothy A Haystead; Jesse J Kwiek Journal: Retrovirology Date: 2017-09-29 Impact factor: 4.602
Authors: Monty Montano; Shalender Bhasin; Richard T D'Aquila; Kristine M Erlandson; William J Evans; Nicholas T Funderburg; Amy Justice; Lishomwa C Ndhlovu; Bisola Ojikutu; Marco Pahor; Savita Pahwa; Alice S Ryan; Jennifer Schrack; Michael B Schultz; Paola Sebastiani; David A Sinclair; Julia Tripp; Bruce Walker; Julie A Womack; Raymond Yung; R Keith Reeves Journal: AIDS Res Hum Retroviruses Date: 2019-09-23 Impact factor: 2.205
Authors: Ninad S Chaudhary; Tobias Kind; Amanda L Willig; Michael S Saag; Sadeep Shrestha; Nicholas Funderburg; Howard W Wiener; E Turner Overton; Marguerite R Irvin Journal: Medicine (Baltimore) Date: 2021-07-30 Impact factor: 1.817
Authors: Dana Gabuzda; Beth D Jamieson; Ronald G Collman; Michael M Lederman; Tricia H Burdo; Steven G Deeks; Dirk P Dittmer; Howard S Fox; Nicholas T Funderburg; Savita G Pahwa; Ivona Pandrea; Cara C Wilson; Peter W Hunt Journal: Pathog Immun Date: 2020-06-17
Authors: Emily R Bowman; Cheryl M Cameron; Brian Richardson; Manjusha Kulkarni; Janelle Gabriel; Morgan J Cichon; Kenneth M Riedl; Yousef Mustafa; Michael Cartwright; Brandon Snyder; Subha V Raman; David A Zidar; Susan L Koletar; Martin P Playford; Nehal N Mehta; Scott F Sieg; Michael L Freeman; Michael M Lederman; Mark J Cameron; Nicholas T Funderburg Journal: PLoS Pathog Date: 2020-10-01 Impact factor: 7.464